Iovance Biotherapeutics, Inc.
IOVA
주식 순위
#2786
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
주가
$14.87
시가총액
$6.74B
변동 (1일)
4.64%
변동 (1년)
540.91%
국가
US
거래 Iovance Biotherapeutics, Inc. (IOVA)
카테고리
Healthcare
Iovance Biotherapeutics, Inc. (IOVA)의 주식 분할 이력
Iovance Biotherapeutics, Inc. 주식 (심볼: IOVA)은 총 2회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Sep 26, 2013에 발생했습니다.
May 26, 2010 이전에 매수한 IOVA 주식 1주는 현재 0.23999주의 IOVA 주식에 해당합니다.
가장 최근의 분할은 Sep 26, 2013에 발생했습니다.
May 26, 2010 이전에 매수한 IOVA 주식 1주는 현재 0.23999주의 IOVA 주식에 해당합니다.
주식 분할 목록
| 연도 | 주식 분할 | 배수 | 누적 배수 |
|---|---|---|---|
| 2013-09-26 | 1:100 | x0.01 | x0.23999 |
| 2010-05-26 | 23999:1000 | x23.999 | x23.999 |
유사 기업 또는 경쟁사의 주식 분할
| 회사 | 주식 분할 횟수 | 누적 배수 | 국가 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
